Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 9Unknown 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 38Lymphoma 38Lung Neoplasms 25Ovarian Neoplasms 24Melanoma 23Neoplasm Metastasis 21Hematologic Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 19Fallopian Tube Neoplasms 19Breast Neoplasms 18Prostatic Neoplasms 17Glioma 17Sarcoma 14Carcinoma, Renal Cell 14Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Lymphoma, Non-Hodgkin 12Urinary Bladder Neoplasms 11Small Cell Lung Carcinoma 11Neoplasms 11Leukemia, Lymphocytic, Chronic, B-Cell 11Glioblastoma 11Triple Negative Breast Neoplasms 10Pancreatic Neoplasms 10Medulloblastoma 10Wilms Tumor 9Sarcoma, Ewing 9Rhabdomyosarcoma 9Rhabdoid Tumor 9

Interventions

venetoclax 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Dexamethasone 1Calcium Dobesilate 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × NIH × Immunoglobulin Light-chain Amyloidosis × Clear all
NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡